Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

On November 17, 2022, Omega Therapeutics (Nasdaq: OMGA) announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 8:00 a.m. ET. The event will showcase Omega's innovative approach to mRNA therapeutics as programmable epigenetic medicines. A live webcast can be accessed on their website, with an archived replay available for 90 days post-event.

Omega focuses on correcting gene expression using its OMEGA Epigenomic Programming platform across various diseases.

CAMBRIDGE, Mass., Nov. 17, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET. 

A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chat will be available on the same website for approximately 90 days.

About Omega Therapeutics

Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The Company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers™, target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.

For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.

Contacts

Investor contact:
Eva Stroynowski
Omega Therapeutics
617.949.4370
estroynowski@omegatx.com 

Media contact:
Jason Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-301679561.html

SOURCE Omega Therapeutics

FAQ

What is Omega Therapeutics participating in on December 1, 2022?

Omega Therapeutics will participate in the Piper Sandler 34th Annual Healthcare Conference.

What time is Omega Therapeutics' fireside chat at the conference?

The fireside chat is scheduled for 8:00 a.m. ET.

Where can I watch the Omega Therapeutics fireside chat?

The fireside chat will be available as a live webcast on Omega Therapeutics' website.

How long will the Omega Therapeutics fireside chat be available for replay?

An archived replay will be available for approximately 90 days.

What is the main focus of Omega Therapeutics?

Omega Therapeutics focuses on mRNA therapeutics as programmable epigenetic medicines to correct gene expression.